CARDIOVASCULAR COMPLICATIONS OF ANTICANCER THERAPY: CLINICAL FEATURES, DIAGNOSIS, TREATMENT, PREVENTION (PART II)
- Authors: Vatutin N.T1,2, Sklyannaya E.V1,2, El-Khatib M.A.1, Taradin G.G1,2
-
Affiliations:
- M. Gorky Donetsk National Medical University
- V.K. Gusak Institute of Emergency and Reconstructive Surgery
- Issue: Vol 23, No 1 (2018)
- Pages: 43-49
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40389
- DOI: https://doi.org/10.18821/1028-9984-2018-23-1-43-49
- ID: 40389
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
N. T Vatutin
M. Gorky Donetsk National Medical University; V.K. Gusak Institute of Emergency and Reconstructive SurgeryDonetsk, 83003, Ukraine; Donetsk, 83045, Ukraine
E. V Sklyannaya
M. Gorky Donetsk National Medical University; V.K. Gusak Institute of Emergency and Reconstructive SurgeryDonetsk, 83003, Ukraine; Donetsk, 83045, Ukraine
Mariam A. El-Khatib
M. Gorky Donetsk National Medical University
Email: el-khatib.mariam@yandex.ru
MD, Assistant Professor of the Department of Hospital Therapy; Donetsk, 83003,Ukraine Donetsk, 83003, Ukraine
G. G Taradin
M. Gorky Donetsk National Medical University; V.K. Gusak Institute of Emergency and Reconstructive SurgeryDonetsk, 83003, Ukraine; Donetsk, 83045, Ukraine
References
- Zamorano J.L., Lancellotti P., Muñoz D.R. et al. ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur. Heart J. 2016; 37(36): 2768-801. doi: 10.1093/eurheartj/ehw211
- Селиверстова Д.В., Евсина О.В. Кардиотоксичность химиотерапии. Сердце: журнал для практикующих врачей. 2016; 15(1): 50-7. doi: 10.18087/rhj.2016.1.2115
- Cardinale D., Colombo A., Colombo N. Acute coronary syndrome induced by oral capecitabine. Can. J. Cardiol. 2006; 22(3): 251-3.
- Ewer M.S., O’Shaughnessy J.A. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin. Breast Cancer. 2007; 7(8): 600-7.
- Матяш М.Г., Кравчук Т.Л., Высоцкая В.В., Чернов В.И., Гольдберг В.Е. Индуцированная антрациклинами кардиотоксичность: механизмы развития и клинические проявления. Сибирский онкологический журнал. 2008; 6: 66-75.
- Калинкина Н.В. Повреждение сердца антрациклинами. Донецк: Каштан; 2008.
- Curigliano G., Cardinale D., Suter T., Plataniotis G., de Azambuja E., Sandri M.T., et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann. Oncol. 2012; 23(Suppl 7): vii155-66:155-66. doi: 10.1093/annonc/mds293.
- Manrique С.R., Park M., Tiwari N., Plana J.C., Garcia MJ. Diagnostic strategies for early recognition of cancer therapeutics-related cardiac dysfunction. Clin. Med. Insights. Cardiol. 2017; 11: 1-12. doi: 10.1177/1179546817697
- Sarkiss M.G., Yusuf S.W., Warneke C.L., Botz G., Lakkis N., Hirch-Ginsburg C., et al. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer. 2007; 109(3): 621-7. doi: 10.1002/cncr.22434.
- Крикунова О.В., Васюк Ю.А., Висков Р.В., Крикунов П.В., Иванова С.В., Коник В.А. Сердечные тропонины в выявлении кардиотоксичности у пациентов, подвергающихся химиотерапии. Российский кардиологический журнал. 2015; 12: 119-25. http://dx.doi.org/10.15829/1560-4071-2015-12-119-125.
- Снеговой А. В., Виценя М. В., Копп М. В., Ларионова В. Б. Практические рекомендации по коррекции кардиоваскулярной токсичности, индуцированной химиотерапией и таргетными препаратами. Злокачественные опухоли. 2015; 4: 369-78.
- Pai V.B., Nahata M.C. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug. Saf. 2000; 22(4): 263-302.
- Antman E.M., Hand M., Armstrong P.W., Bates E.R., Green L.A., Halasyamani L.K. et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2008; 51(2): 210-47.
- Lipshultz S.E., Franco V.I., Miller T.L., Colan S.D., Sallan S.E. Cardiovascular disease in adult survivors of childhood cancer. Annu. Rev. Med. 2015; 66: 161-76. doi: 10.1146/annurev-med-070213-054849.
- Pande A., Lombardo J., Spangenthal E., Javle M. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res. 2007; 27(5B): 3465-70.
- Chobanian A.V., Bakris G.L., Black H.R., Green L.A., Izzo J.L. Jr, Jones D.W. et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6): 1206-52. doi: 10.1161/01.HYP.0000107251.49515.c2.
- Rixe O., Billemont B., Izzedine H. Hypertension as a predictive factor of sunitinib activity. Ann. Oncol. 2007; 18(6): 1117.
- Kearon C., Kahn S.R., Agnelli G., Goldhaber S., Raskob G.E., Comerota A.J. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133(Suppl.6): 454S-545S. doi: 10.1378/chest.08-0658.
- Gupta A., Lawrence A.T., Krishnan K., Kavinsky C.J., Trohman R.G. Current concepts in the mechanisms and management of druginduced QT prolongation and torsade de pointes. Am. Heart J. 2007; 153(6): 891-9. doi: 10.1016/j.ahj.2007.01.040.
- Palumbo A., Rajkumar S.V., Dimopoulos M.A., Richardson P.G., San Miguel J., Barlogie B., et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008; 22(2): 414-23. doi: 10.1038/sj.leu.2405062.
- Yeh E.T., Bickford C.L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol. 2009; 53(24): 2231-47. doi: 10.1016/j.jacc.2009.02.050.
- Chu T.F., Rupnick M.A., Kerkela R., Dallabrida S.M., Zurakowski D., Nguyen L., et al. Cardiotoxicity associated with tyrosinekinase inhibitor sunitinib. Lancet. 2007; 370(9604): 2011-9. doi: 10.1016/S0140-6736(07)61865-0.
- Palumbo A., Rajkumar S.V., Dimopoulos M.A., Richardson P.G., San Miguel J., Barlogie B., et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008; 22(2): 414-23. doi: 10.1038/sj.leu.2405062.
- Senkus E., Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat. Rev. 2011; 37(4): 300-11. doi: 10.1016/j.ctrv.2010.11.001.
- Yeh E.T., Tong A.T., Lenihan D.J., Yusuf S.W., Swafford J., Champion C., et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004; 109(25): 3122-31. doi: 10.1161/01.CIR.0000133187.74800.B9.
- Suter T.M., Ewer M.S. Cancer drugs and the heart: importance and management. Eur. Heart J. 2013; 34 (15): 1102-11. doi: 10.1093/eurheartj/ehs181.
- Гендлин Г.Е., Емелина Е.И., Никитин И.Г., Васюк Ю.А. Современный взгляд на кардиотоксичность химиотерапии онкологических заболеваний, включающей антрациклиновые антибиотики. Российский кардиологический журнал 2017; 3: 145-54. doi: 10.15829/1560-4071-2017-3-145-154
- Ewer M.S., Swain S.M., Cardinale D., Fadol A., Suter T.M. Cardiac dysfunction after cancer treatment. Tex. Heart Inst. J. 2011; 38(3): 248-52.
- Hrdina R., Gersl V., Klimtova I., Simunek T., Machackova J., Adamcova M. Anthracycline-induced cardiotoxicity. Acta Medica (Hradec Kralove). 2000; 43(3): 75-82.
- Miolo G.M., La Mura N., Nigri P., Murrone A., Da Ronch L., Viel E. et al. The cardiotoxicity of chemotherapy: New prospects for an old problem. Radiol Oncol. 2006; 40(3): 149-61.